- Home
- STTK vs ACHL Comparison
STTK vs ACHL Comparison
Compare STTK & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ACHL
- Stock Information
- Founded
- STTK 2016
- ACHL 2016
- Country
- STTK United States
- ACHL United Kingdom
- Employees
- STTK N/A
- ACHL N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STTK Health Care
- ACHL Health Care
- Exchange
- STTK Nasdaq
- ACHL Nasdaq
- Market Cap
- STTK 56.8M
- ACHL 46.0M
- IPO Year
- STTK 2020
- ACHL 2021
- Fundamental
- Price
- STTK $1.37
- ACHL $1.38
- Analyst Decision
- STTK Hold
- ACHL Buy
- Analyst Count
- STTK 3
- ACHL 2
- Target Price
- STTK $2.00
- ACHL $4.00
- AVG Volume (30 Days)
- STTK 131.9K
- ACHL 1.9M
- Earning Date
- STTK 03-03-2025
- ACHL 04-03-2025
- Dividend Yield
- STTK N/A
- ACHL N/A
- EPS Growth
- STTK N/A
- ACHL N/A
- EPS
- STTK N/A
- ACHL N/A
- Revenue
- STTK $6,435,000.00
- ACHL N/A
- Revenue This Year
- STTK $313.04
- ACHL N/A
- Revenue Next Year
- STTK N/A
- ACHL N/A
- P/E Ratio
- STTK N/A
- ACHL N/A
- Revenue Growth
- STTK 382.75
- ACHL N/A
- 52 Week Low
- STTK $0.94
- ACHL $0.63
- 52 Week High
- STTK $11.76
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- STTK 60.23
- ACHL 72.41
- Support Level
- STTK $1.21
- ACHL $1.10
- Resistance Level
- STTK $1.36
- ACHL $1.41
- Average True Range (ATR)
- STTK 0.10
- ACHL 0.02
- MACD
- STTK 0.01
- ACHL 0.00
- Stochastic Oscillator
- STTK 90.00
- ACHL 90.48
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.